Top

14-08-2024 | Metabolic Dysfunction-Associated Steatotic Liver Disease | Podcast

Episode 13

Advances in MASLD and MASH

Welcoming a new name and a new treatment

Guest:

Prof. Vlad Ratziu

Professor of Hepatology

Sorbonne University, Paris, France.

Host:

Dr. Natalie Wood

Senior Clinical Content Manager, Springer Medicine

Metabolic dysfunction-associated liver disease is a significant healthcare concern and burden. Until recently there was no approved pharmacologic treatment for the more serious form of the disease, metabolic dysfunction-associated steatohepatitis.

In this wide-ranging conversation, Prof. Vlad Ratziu explains the rationale behind the recently updated subclassification and nomenclature for steatotic liver disease, puts the therapeutic advance of resmetirom into context, and looks to the future for MASLD and MASH.

« Previous episode: Episode 12: Defining ARDS

Next episode: Episode 14: Diagnostic criteria for AD »

Related topics

Keynote series | Spotlight on managing health in obesity

Obesity
Video Series

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Prof. Eva L. Feldman

Prof. Jonette Keri

Developed by: Springer Medicine

Watch now

Women’s health knowledge hub

Menopause
Clinical Collection

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Live
Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital

Prof. Ronald F. van Vollenhoven